What is Immuneering?
Immuneering is a specialized clinical-stage oncology company dedicated to the development and commercialization of universal-RAS/RAF medicines. The firm's core technological advantage lies in its Deep Cyclic Inhibition of the MAPK pathway, a mechanism designed to maximize efficacy against cancer cells while minimizing toxicity to healthy tissue. Its lead product candidate, IMM-1-104, is currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors harboring RAS mutations. Additionally, the company is progressing with IMM-6-415, which targets RAS or RAF mutations, further diversifying its therapeutic portfolio. By focusing on broad patient populations, Immuneering aims to address significant unmet needs in oncology through precision medicine and innovative pharmacological strategies.
How much funding has Immuneering raised?
Immuneering has raised a total of $219.5M across 4 funding rounds:
Series A
$20M
Series B
$62M
Share Placement
$112.5M
Private Equity
$25M
Series A (2020): $20M with participation from Boxcar PMJ LLC
Series B (2021): $62M led by Rock Springs Capital, Perceptive Advisors, Cormorant Asset Management, T. Rowe Price, BlackRock, LYFE Capital, and Surveyor Capital
Share Placement (2021): $112.5M, investors not publicly disclosed
Private Equity (2025): $25M, investors not publicly disclosed
Key Investors in Immuneering
Perceptive Advisors
Founded in 1999, Perceptive Advisors is a New York-based investment firm managing significant assets with a specialized focus on funding innovative healthcare and life sciences technologies.
Cormorant Asset Management
Cormorant Asset Management is a prominent life sciences investment firm that prioritizes fundamental scientific principles to support promising companies in the biotech and allied sectors.
T. Rowe Price
T. Rowe Price is a global investment management firm that provides comprehensive financial services and manages equity and fixed income funds for institutional and individual investors worldwide.
What's next for Immuneering?
With the successful completion of this major strategic investment, Immuneering is well-positioned to scale its clinical operations and deepen its research into the MAPK pathway. The company's immediate focus will likely center on the continued execution of its Phase 1/2a trials for IMM-1-104 and IMM-6-415, with an eye toward generating robust clinical data to support future regulatory filings. As the firm transitions into a more mature enterprise-level entity, the strategic deployment of this capital will be essential for maintaining its competitive edge in the biotech landscape. Future growth will likely involve the expansion of its early-stage pipeline and potential partnerships to enhance the commercialization prospects of its lead candidates, ensuring that its innovative therapies reach patients in need of effective, targeted oncology solutions.
See full Immuneering company page
